Summary of Purpose
To determine the safety of Argatroban injection and its optimum effective doses in patients with acute ischemic stroke.Read More →
The following dates are available for this trial. Trial information last updated on 28 July 2008.
|Start Date||First Received||1st Completion||Completion||Verification||Results|
- Texas Biotechnology Corporation, Mitsubishi-Tokyo Pharmaceuticals
Randomized, blinded, placebo-controlled, three-treatment-arm trial with an anticipated enrollment of 180 patients at 55 centers.